Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.
about
Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease PathogenesisModulation of host adaptive immunity by hRSV proteinsSynthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial VirusRSV fusion: time for a new modelRespiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virusVaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responsesEffects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infectionTreatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in miceProphylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvantViral load drives disease in humans experimentally infected with respiratory syncytial virusAssembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.Therapeutic targeting of respiratory syncytial virus G-protein.The viral KSHV chemokine vMIP-II inhibits the migration of Naive and activated human NK cells by antagonizing two distinct chemokine receptors.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsEffect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection.An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in miceMonoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced DiseasesCX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and DiseaseViral and host factors in human respiratory syncytial virus pathogenesis.Live-attenuated respiratory syncytial virus vaccines.Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenicNonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activationIntracellular protease activation in apoptosis and cell-mediated cytotoxicity characterized by cell-permeable fluorogenic protease substrates.Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunctionRole of perforin-mediated cell apoptosis in murine models of infusion-induced bone marrow failure.Human metapneumovirus establishes persistent infection in the lungs of mice and is reactivated by glucocorticoid treatment.A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.The host response and molecular pathogenesis associated with respiratory syncytial virus infection.
P2860
Q26823449-597F0BFE-3FBD-4D39-9104-A0379038B86FQ27022693-54E68D43-45BB-447E-8C3E-0DE0D074591DQ28067143-9182253B-B512-4C16-9606-FFBF234F4408Q28287657-96CADBDC-7156-430D-8A27-FCBF72A92788Q28545124-4DE5B2CA-0983-4396-B178-7E76DE0ED6F4Q33558356-D51BAEBB-3923-476C-A01F-27891BEBE9F7Q33558475-38FAD78D-DD26-4109-9B00-84C7A4248344Q33754172-1E9CC00E-95A3-4DCD-9361-071A93AC13ABQ33881536-3ACCC88E-A12C-4348-BD3B-84209C4978B4Q33920501-CB75DBBE-FC9A-47F4-8BFC-FF1E990292B8Q34120278-D608F20D-8F1C-4202-846D-473AA5F78587Q34182385-024A1F8D-CD72-4D9A-8171-27B31B0CB381Q34402459-F00D0AB8-637D-4FC8-AE1A-3DEE2F6DEEBAQ34457791-E394358E-99FB-4550-A11C-2125029B7621Q34540179-80116CCA-1DCA-4827-9770-B1EDBB1FFB50Q34603346-DA8935BA-9E77-4435-84CD-72E059005A07Q34961799-76C1D8A2-2FC3-4D04-9BD7-21C50B3108ADQ34990420-06EE6E2F-383C-436A-991B-DBC6A81EA9C0Q35566601-DAFB112E-395A-4C6A-9A00-0E530533F66BQ35747504-CD26442A-9167-4677-AA54-A55719457627Q35893983-E027CDFC-FAEE-4E0F-8DF7-6C71E3F7FB40Q36005114-1D7E89B2-5C86-4FE6-AE39-BACB63F69149Q36106575-942E59E2-242F-4216-A0DE-E181755C0874Q36246429-DD537514-F5BC-4F5C-A641-0825B9691A97Q36255118-34AD20EF-3DF4-48E6-BD9A-71528D81D3A0Q36409517-3919CB30-2C48-4539-8F26-2961CF6E3ABEQ36483836-41456DEE-C9F5-4DBD-9DA4-6B650536CF21Q36692801-4BBBBC0C-7709-4255-A76C-5AB0C0472F59Q36823131-09599E21-105C-4084-BC99-108D6B7DAE83Q36845814-B275038A-A357-40FA-9484-771AC87ED487Q36994686-D17A48BC-1E95-4C02-825D-94FE90E3A899Q36994716-B2CF6AD5-2709-4899-B2A5-6B7D741E781CQ37001936-48688119-62CC-42B2-ACEF-7E665D0C2433Q37070264-2140FD10-8016-4F71-87B8-75B11DB79A0FQ37071608-C039B39F-39CB-4053-9D33-A4AD3CF36485Q37157161-9DA60C94-4CBF-4DD5-9526-EF6535BABBF1Q37217855-FCF72538-540B-41CC-AE8C-AE99090279F1Q37232888-DDEE13FC-2D79-4263-A4C4-5FBE20542E73Q37252613-728BF949-7C5A-43BB-9DAB-D245A71D0B0DQ37263779-A61D6303-DEA8-4797-B0BC-680143FBEA9B
P2860
Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@ast
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@en
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@nl
type
label
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@ast
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@en
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@nl
prefLabel
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@ast
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@en
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@nl
P2093
P1476
Respiratory syncytial virus G ...... fect CX3CR1+ T cell responses.
@en
P2093
Christine Henderson
Jennifer Harcourt
Larry J Anderson
Les P Jones
Ralph A Tripp
Rene Alvarez
P304
P356
10.4049/JIMMUNOL.176.3.1600
P407
P577
2006-02-01T00:00:00Z